Recruiting

Early Phase 1

TroriluzoleA Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

Sponsor:

Ugonma Chukwueke

Code:

NCT06552260

Conditions

Glioblastoma

Recurrent Glioblastoma

Brain Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Troriluzole

Study Details

Brief summary:

This research study is studying troriluzole as a possible treatment for recurrent glioblastoma.

The name of the study drug involved in this research study is:

-Troriluzole (a tripeptide prodrug of riluzole)

Conditions

Glioblastoma

Recurrent Glioblastoma

Brain Tumor

Study ID

NCT06552260

Start date

Feb 19, 2025

Status verified date

Aug, 2025

Completion date

Aug 1, 2027

Anticipated

Primary completion date

Aug 1, 2026

Anticipated

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Age ≥18 years
Histopathologically confirmed IDH-wildtype glioblastoma, WHO Grade 4, and variants including gliosarcoma as per WHO 2021 criteria (38).
Prior treatment with radiotherapy with or without chemotherapy.
Recurrent or progressive disease with no more than 2 prior relapses.
Confirmed measurable disease per RANO 2.0 for GBM.
Tumor is documented as IDH1/2 wildtype by direct DNA sequencing, provided that it is performed in a CLIA/CAP-certified laboratory.
Availability of archival formalin fixed paraffin-embedded (FFPE) tumor tissue block or 20 unstained FFPE slides (5 μm thick) from any prior surgery for mutation testing and additional sequencing.
Karnofsky Performance Status of ≥ 60.
Candidate for surgical resection.
Tumor tissue extending to cortical gray matter based on MRI.
Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better.
Women of child-bearing potential (WOCBP), defined as any individual assigned female at birth physiologically capable of becoming pregnant, must use highly effective contraception during study treatment and for 1 month after study discontinuation. Highly effective contraception is defined as either:

True Abstinence: When this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.
Sterilization: Surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
Male Partner Sterilization (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate). For female subjects on the study, the vasectomised male partner should be the sole partner for that participant.
A barrier method defined as condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository along with a second contraceptive method as described below:

Placement of an intrauterine device (IUD) or intrauterine system (IUS)
Appropriate hormonal contraceptives (including any registered and marketed contraceptive agent that contains an estrogen and/or a progestational agent - including oral, subcutaneous, intrauterine
Male subjects should agree to use a highly effective method of contraception starting with the first dose of study therapy through 3 months after the last dose of therapy. Male subjects must not donate semen for 3 months after the last dose of study treatment.
Ability to understand and the willingness to sign a written informed consent document. (Providing consents in as many languages as possible is encouraged)

Exclusion Criteria:

Laboratory values at the Screening Visit:

ANC count < 1,500/mm3; growth-factor support within 7 days for filgrastim or other short acting biosimilars or 21 days for pegfilgrastim or other long acting biosimilars to increase the ANC is not allowed.
Platelets <100,000/mm3;
Hemoglobin < 9 g/dL;
Total bilirubin > 2 × the upper limit of normal (ULN) (unless subject has documented history of Gilbert's Syndrome in which case subject may be enrolled if total bilirubin is less than 5 mg/dL, assuming all other criteria are fulfilled);
Aspartate aminotransferase (AST \[SGOT\]) > 1.5 x ULN;
Alanine aminotransferase (ALT \[SGPT\]) > 1.5 x ULN;
Serum creatinine > 1.5 mg/dL or a calculated creatinine clearance < 60 mL/min; and
Positive serum β-hCG test in any individual assigned female at birth and is of childbearing potential (defined as ≤ 50 years of age, or > 50 years of age with a history of amenorrhea for ≤12 months prior to study entry).
Has presence of diffuse leptomeningeal disease or extracranial disease.
Prior treatment with troriluzole or riluzole
From study treatment initiation, treatment with temozolomide less than 23 days, treatment with CCNU or BCNU less than 42 days, treatment with anti-VEGF therapy such as bevacizumab less than 6 months, or treatment with any cancer-directed systemic therapy less than 4 weeks or 5 half-lives, whichever is shorter. No wash-out period is required from tumor treating fields (TTF).
Use of any investigational agents within 28 days of baseline or 5 half-lives from study initiation, whichever is shorter.
Radiotherapy within 12 weeks prior to registration unless new enhancement is outside the radiation field (beyond the high-dose region of 80% isodense line) or evidence of viable tumor on histopathologic sampling.
Presence of a clinically significant allergy, hypersensitivity, or toxicity of prior therapy, with the exception of alopecia or lymphopenia, that has not resolved to ≤ Grade 1 or pre-treatment baseline, as determined by National Cancer Institute CTCAE v 5.0.
Major surgery within 28 days prior to initiation of study drug.
Active or clinically unstable bacterial, viral, or fungal infection requiring systemic therapy.
Any contraindication to MRI examination.
Requires medications that are known to be strong inhibitors or inducers of CYP1A2 enzymes or anti-glutamergic agents (e.g., perampanel) or hepatotoxic drugs which may increase the risk of hepatotoxicity (e.g., allopurinol, methyldopa, sulfasalazine). A washout of 10 days or 5 half-lives, whichever is shorter, is required prior to study treatment initiation. Oral contraceptives which contain ethinyl estradiol (moderate CYP1A2 inhibitor) are allowed.
Pregnant or lactating female.
History of interstitial lung disease.
Known history of hepatitis B, human immunodeficiency virus (HIV), or active hepatitis C infection requiring treatment with antiviral therapy. NOTE: HIV testing is not required in the absence of clinical suspicion.
Any severe, acute, or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, may interfere with the informed consent process and/or with compliance with the requirements of the study, or may interfere with the interpretation of study results and, in the Investigator's opinion, would make the subject inappropriate for entry into this study.
Difficulty swallowing or malabsorption syndrome; refractory nausea and vomiting, chronic gastrointestinal (GI) disease or previous significant bowel resection with clinically significant sequelae that would preclude adequate absorption of study drug.

Study Design

Enrollment

27 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Group A: Presurgical Troriluzole

18 participants will be randomly assigned to this group and with complete:

Baseline visit with assessments and MRI.
Cycle 0:

Day -6 through Day 0: Predetermined dose of Troriluzole 2x daily.
Day 0: pre-op MRI
Day 0: standard of care surgical resection of tumor
Day 0: post-op MRI
Cycle 1 through Cycle 3:

--Days 1 through 28 of 28 day cycle: Predetermined dose of Troriluzole 2x daily.

Cycle 3 through End of Treatment:

--Days 1 through 28 of 28 day cycle: Predetermined dose of Troriluzole 2x daily.

MRIs every 8 weeks while on treatment.
End of study visit with MRI
Follow up every 3 months for 1 year, and then every 6 months for the next 3 years.

experimental: Group B: Surgery + Troriluzole

9 participants will be randomly assigned to this group and with complete:

Baseline visit with assessments and MRI
Day 0: pre-op MRI
Day 0: standard of care surgical resection of tumor
Day 0: post-op MRI
Cycle 1 through Cycle 3:

--Days 1 through 28 of 28 day cycle: Predetermined dose of Troriluzole 2x daily.

Cycle 3 through End of Treatment:

--Days 1 through 28 of 28 day cycle: Predetermined dose of Troriluzole 2x daily.

MRIs every 8 weeks while on treatment.
End of study visit with MRI
Follow up every 3 months for 1 year, and then every 6 months for the next 3 years.

Interventions

Troriluzole

Tripeptide prodrug of Riluzole, 100 mg capsule, taken orally per protocol.

Primary outcome measure

The effect of troriluzole on high-gamma band power (a measure of neuronal activity) via electrocorticography during surgical resection [ Time Frame: At time of surgery ]

Central Contacts and Locations

Central contacts

Ugonma Chukwueke, MD

617-632-2166 Ugonma_Chukwueke@DFCI.HARVARD.EDU

Locations

Brigham and Women's Hospital

Recruiting

Boston, Massachusetts, United States, 02215

Contacts

Ugonma Chukwueke, MD

617-632-2166 Ugonma_Chukwueke@DFCI.HARVARD.EDU

Principal Investigator:

Ugonma Chukwueke, MD

Dana-Farber Cancer Institute

Recruiting

Boston, Massachusetts, United States, 02215

Contacts

Ugonma Chukwueke, MD

617-632-2166 Ugonma_Chukwueke@DFCI.HARVARD.EDU

Principal Investigator:

Ugonma Chukwueke, MD

Massachusetts General Hospital Cancer Center

Recruiting

Boston, Massachusetts, United States, 02215

Contacts

Isabel Arrillaga-Romany, MPH, PhD

iarrillaga@mgh.harvard.edu

Principal Investigator:

Isabel Arrillaga-Romany, MD, PhD

More Information

Sponsor

Ugonma Chukwueke

Last update posted

Sep 11, 2025

Last verified

Aug, 2025

Keywords

Glioblastoma
Recurrent Glioblastoma
Brain Tumor
Isocitrate dehydrogenase wild-type Glioblastoma

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Ugonma Chukwueke on 2025-09-11.